{
    "clinical_study": {
        "@rank": "95901", 
        "arm_group": [
            {
                "arm_group_label": "A3384 Low dose", 
                "arm_group_type": "Experimental", 
                "description": "Administered twice daily for the duration of the study"
            }, 
            {
                "arm_group_label": "A3384 High dose", 
                "arm_group_type": "Experimental", 
                "description": "Administered twice daily for the duration of the study"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Administered twice daily for the duration of the study"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to determine the efficacy and safety of A3384 administered to\n      patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)."
        }, 
        "brief_title": "Double-blind, Randomised Study of A3384 in BAM/BAD", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Bile Acid Malabsorption", 
        "condition_browse": {
            "mesh_term": "Malabsorption Syndromes"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient meets protocol specified criteria for Bile Acid Malabsorption/Bile Acid\n             Diarrhoea\n\n          -  Patient has successfully completed study requirements with no clinically relevant\n             findings for physical exam, ECG, laboratory tests as applicable\n\n        Exclusion Criteria:\n\n          -  Medical history or medical condition that would not make the patient a good candidate\n             for the study or limit the patient\u00b4s ability to complete the study\n\n          -  Patient needs medications prohibited as specified in the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078856", 
            "org_study_id": "A3384-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "A3384 Low dose", 
                "A3384 High dose", 
                "Placebo"
            ], 
            "intervention_name": "A3384", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "r.appleby@imperial.ac.uk", 
                "last_name": "Richard Appleby, MD"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "W12 0HS"
                }, 
                "name": "Hammersmith Hospital, Imperial College Healthcare NHS Trust"
            }, 
            "investigator": {
                "last_name": "Julian R Walters, MBBS MA FRCP", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of A3384 in Patients With Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)", 
        "overall_contact": {
            "email": "hans.graffner@albireopharma.com", 
            "last_name": "Hans Graffner, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary efficacy objective of this study is to demonstrate the efficacy of different daily doses of A3384 as determined by the # of bowel movements (BMs).", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078856"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change from Baseline in average severity of diarrhoea during the second treatment week (last 7 days of reporting).\nChange from Baseline in average severity of abdominal discomfort during the second treatment week (last 7 days of reporting).\nChange from Baseline in average severity of abdominal bloating during the second treatment week (last 7 days of reporting).\nChange from Baseline in average BSFS during the second treatment week (last 7 days of reporting)", 
            "measure": "Secondary efficacy objectives of this study are to demonstrate the efficacy of different daily doses on other BM parameters and BAM/BAD symptoms", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 2 weeks"
        }, 
        "source": "Albireo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Albireo", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}